Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Metrics to compare | ZELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZELAPeersSector | |
---|---|---|---|---|
P/E Ratio | −49.0x | −5.4x | −0.7x | |
PEG Ratio | 2.98 | 0.05 | 0.00 | |
Price/Book | 5.8x | 2.3x | 2.6x | |
Price / LTM Sales | 670.9x | 6.7x | 3.2x | |
Upside (Analyst Target) | 47.9% | 56.3% | 44.5% | |
Fair Value Upside | Unlock | 5.8% | 6.6% | Unlock |